Familial episodic pain syndrome

Lore & Background

Familial episodic pain syndrome was first described in 2010 when Kremeyer et al. reported FEPS Type 1 in 21 affected members from a large 4-generation Colombian family. This type is characterized by infancy-onset intense and debilitating upper-body episodic pain, caused by mutations in the TRPA1 gene on chromosome 8. In 2012, Faber et al. described FEPS Type 2 in a 2-generation family (a man and his son), with adult-onset episodic paroxysmal pain in the distal lower limbs; the proband developed symptoms at age 57 and his son at age 39, caused by mutations in the SCN10A gene on chromosome 3.

Reader's Guide

Familial episodic pain syndrome represents a distinct category of inherited pain disorders that highlight the genetic basis of pain perception. The identification of three types, each linked to specific gene mutations (TRPA1, SCN10A, and SCN11A), has advanced understanding of peripheral neuropathy mechanisms. FEPS Type 3, described in two large Chinese families and 12 unrelated patients, shows childhood-onset pain that can be treated with anti-inflammatory medication and tends to decrease in severity with age. The autosomal dominant transmission pattern across all types underscores the hereditary nature of these conditions. The syndrome's rarity and the variability in age of onset—from infancy to late adulthood—pose diagnostic challenges. The discovery of these genetic causes has opened avenues for targeted research into pain pathways, though treatment remains largely symptomatic. The condition's episodic nature and triggers such as cold or exercise provide clinical clues for diagnosis.

Did You Know?

• FEPS Type 1 was first described in 2010 in 21 affected members from a large 4-generation Colombian family.
• FEPS Type 2 was first described in 2012 in a man and his son, with the father developing symptoms at age 57.
• Only FEPS Type 1 (TRPA1) and FEPS Type 2 (SCN10A) are widely recognized in medical literature; no established Type 3 exists.
• Both established types are transmitted in an autosomal dominant pattern.

Discovery & Taxonomic Place

In 1949, physicians Conrad Milton Riley and Richard Lawrence Day first described what would come to bear their names as a syndrome. Their observations laid the groundwork for understanding a rare, progressive condition inherited in a recessive pattern, one that fundamentally disrupts how the autonomic nervous system builds and maintains its neural architecture. Specifically, the disorder impairs the development and long-term survival of sensory neurons, sympathetic neurons, and a subset of parasympathetic neurons, leaving the body's automatic regulatory systems—heart rate, blood pressure, temperature, digestion—permanently compromised. Familial dysautonomia sits within a broader family of conditions called hereditary sensory and autonomic neuropathies, or HSANs. Every member of this group shares the hallmark of widespread sensory loss paired with fluctuating autonomic failure, both traceable to incomplete maturation of the relevant neuron populations. Importantly, the individual HSAN subtypes are considered genetically separate entities rather than different expressions of a single defect, making FD a distinct chapter in a larger story of neural development gone awry.

The Daily Reality: Autonomic Crises and Pain

Living with familial dysautonomia means navigating a body that misreads its own signals. The most dramatic manifestation is the autonomic crisis: a storm of vomiting that can strike every fifteen to twenty minutes for more than twenty-four hours at a stretch. These episodes, often ignited by infection or emotional upset, are accompanied by surging blood pressure, drenching perspiration, rapid heartbeat, fever, breathing difficulty, and a visible flushing of the skin. Aspiration of vomit can tip the crisis into pneumonia, compounding an already fragile respiratory picture. Equally defining is the altered relationship with pain. Because sensory neurons are underdeveloped, affected individuals may not register sharp or burning stimuli that would cause most people to recoil. The consequence is a cycle of accidental injury—burns, deep ulcers, and in toddlers, compulsive biting of the tongue, lips, and cheeks during teething. Repeated oral trauma can produce the characteristic Riga-Fede lesions, where ulcerated tissue swells into tumour-like masses. The absence of overflow tears during crying, the smooth glossy tongue stripped of its fungiform papillae, and a blunted sense of sweetness round out a sensory landscape that is quietly, profoundly different from the norm.

A Lifelong Progression: From Womb to Adulthood

The trajectory of familial dysautonomia unfolds in recognizable stages, each layering new challenges onto the last. Even before birth, the pattern is visible: a high incidence of breech presentation, lower birth weight relative to siblings, premature delivery, and restricted growth in utero. In the neonatal window, affected infants may show low muscle tone, breathing difficulty, trouble with suckling and swallowing, and early corneal problems. By seven months of age, the telltale absence of overflow tears during emotional crying becomes a reliable clue, since unaffected infants typically begin producing them around two to three months. Hands may alternate between cool and mottled or red and swollen as vascular tone swings unpredictably. Breath-holding spells, which can cause cyanosis or fainting, tend to fade by age six. School years bring bed-wetting, recurrent vomiting storms, and the first learning difficulties—present in roughly a third of those affected, sometimes necessitating special education. Scoliosis, fragile bones, and emerging kidney and cardiac strain add further pressure. By adolescence and adulthood, cumulative respiratory damage, declining renal function, optic-nerve atrophy with vision loss, and progressive balance problems that challenge unaided walking define the later chapters of life.

The Genetic Root: IKBKAP and the IKAP Protein

At the molecular level, familial dysautonomia traces back to mutations in a single gene—IKBKAP—located on chromosome 9. This gene encodes the IKAP protein, formally named IkB kinase complex-associated protein. To date, three distinct mutations in IKBKAP have been identified among individuals living with the condition, and because the disorder follows a recessive inheritance pattern, a child must inherit a faulty copy from each parent before symptoms manifest. The IKAP protein's precise role in neuron biology is still being unpacked, but its loss or dysfunction clearly derails the normal maturation and long-term survival of the very neurons that govern sensation, sympathetic tone, and portions of parasympathetic control. The result is not a single broken switch but a cascading failure across multiple organ systems: the gut loses coordinated motility, the cardiovascular system loses stable pressure regulation, the eyes lose their tear-producing capacity, and the skin loses reliable temperature and pain feedback. Understanding IKBKAP has given researchers a concrete molecular target, anchoring what was once a purely descriptive clinical syndrome to a defined genetic mechanism and opening the door to future therapeutic strategies aimed at the protein itself.